Down 63%, Should You Buy the Dip on Pfizer?
Pfizer has taken its lumps lately. It's time to wonder whether the stock can make a comeback.
It's been a tough go for Pfizer (NYSE: PFE). Shares of the pharmaceutical giant are down over 60% from their highs, a multi-year slide since pandemic-related sales peaked a few years ago. But that's not all. Now, new challenges are putting pressure on the stock.
Stocks aren't always on sale just because their prices went down, but Pfizer's storied history and 7.3% dividend yield make it worth checking under the hood to see if the company has what it takes to get back on track.
So, that's precisely what this Fool did. Here is why Pfizer can't seem to get off the mat and whether it's worth buying the dip on today.
